PCA
AVNS

Pallas Capital Advisors’s Avanos Medical AVNS Stock Holding History

Pallas Capital Advisors’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,208
Closed -$118K – 886
2025
Q3 		$118K Buy
+10,208
New +$120K ﹤0.01% 822

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pallas Capital Advisors's AVNS Position: Q4 2025 in Review

Pallas Capital Advisors sold out of Avanos Medical (AVNS) in Q4 2025, closing a stake of 10,208 shares — an estimated $118K sold.

Pallas Capital Advisors first reported a position in AVNS in Q3 2025 and held it in 1 quarter. The position peaked at $118K in Q3 2025. 274 funds tracked by Wall St. Rank hold AVNS as of Q4 2025.

  • Pallas Capital Advisors reported no remaining Avanos Medical position as of Q4 2025 after selling out during the quarter.
  • Pallas Capital Advisors sold 10,208 Avanos Medical shares in Q4 2025, an estimated $118K.
  • Pallas Capital Advisors first reported a position in Avanos Medical in Q3 2025 and held it in 1 quarter.
  • Pallas Capital Advisors's Avanos Medical position peaked at $118K in Q3 2025.
  • 274 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2025.

Based on Pallas Capital Advisors's 13F filing for Q4 2025, filed 14 Jan 2026.